VERACYTE INC (VCYT)
US92337F1075 - Common Stock
VCYT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. VCYT has a great financial health rating, but its profitability evaluates not so good. VCYT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VCYT had negative earnings in the past year.
VCYT had a positive operating cash flow in the past year.
In the past 5 years VCYT always reported negative net income.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
VCYT has a better Return On Assets (-6.67%) than 91.11% of its industry peers.
VCYT's Return On Equity of -7.13% is amongst the best of the industry. VCYT outperforms 92.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.67% | ||
| ROE | -7.13% | ||
| ROIC | N/A |
ROA(3y)-5.4%
ROA(5y)-5.68%
ROE(3y)-5.81%
ROE(5y)-6.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT has a better Gross Margin (68.73%) than 83.76% of its industry peers.
VCYT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VCYT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y1.43%
2. Health
2.1 Basic Checks
VCYT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VCYT has more shares outstanding
VCYT has more shares outstanding than it did 5 years ago.
VCYT has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 15.09 indicates that VCYT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 15.09, VCYT belongs to the top of the industry, outperforming 89.57% of the companies in the same industry.
VCYT has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
VCYT's Debt to FCF ratio of 0.00 is amongst the best of the industry. VCYT outperforms 98.29% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that VCYT is not too dependend on debt financing.
The Debt to Equity ratio of VCYT (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.09 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 4.66 indicates that VCYT has no problem at all paying its short term obligations.
VCYT has a Current ratio (4.66) which is in line with its industry peers.
VCYT has a Quick Ratio of 4.40. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VCYT (4.40) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.66 | ||
| Quick Ratio | 4.4 |
3. Growth
3.1 Past
The earnings per share for VCYT have decreased strongly by -129.27% in the last year.
VCYT shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.77%.
VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.45% yearly.
EPS 1Y (TTM)-129.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q81.82%
Revenue 1Y (TTM)21.77%
Revenue growth 3Y45.38%
Revenue growth 5Y31.45%
Revenue growth Q2Q17.5%
3.2 Future
The Earnings Per Share is expected to grow by 30.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.45% on average over the next years. This is quite good.
EPS Next Y70.72%
EPS Next 2Y41.32%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue Next Year12.12%
Revenue Next 2Y11.78%
Revenue Next 3Y11.45%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
VCYT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VCYT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.85% of the companies listed in the same industry.
VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 96.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.05 | ||
| EV/EBITDA | 161.62 |
4.3 Compensation for Growth
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 30.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.32%
EPS Next 3Y30.31%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERACYTE INC
NASDAQ:VCYT (5/17/2024, 7:00:02 PM)
After market: 22.73 -0.15 (-0.66%)22.88
-0.52 (-2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.67% | ||
| ROE | -7.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.66 | ||
| Quick Ratio | 4.4 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-129.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y70.72%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.77%
Revenue growth 3Y45.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y